Royalty Pharma plc (NASDAQ:RPRX) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET
Company Participants
Pablo Legorreta - Chief Executive Officer
Marshall Urist - Executive Vice President, Head of Research and Investment
Terrance Coyne - Executive Vice President, Chief Financial Officer
Chris Hite - Executive Vice President, Vice Chairman
George Grofik - Head of Investor Relations and Communications
Conference Call Participants
Chris Shibutani - Goldman Sachs
Hardik Parekh - JP Morgan
Geoff Meacham - Bank of America
Terence Flynn - Morgan Stanley
Andrew Baum - Citi
Mike DiFiore - Evercore
Steven Scala - Cowen
Operator
Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma second quarter earnings conference call. I would now like to turn the call over to George Grofik, Senior Vice President, Head of Investor Relations and Communications. Please go ahead, sir.
George Grofik
Good morning and good afternoon to everyone on the call. Thank you for joining us to review Royalty Pharma’s second quarter 2023 results. You can find a press release with our earnings results and slides for this call on the Investors page of our website at royaltypharma.com.
Moving to Slide 3, I would like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from these statements. I refer to our 10-Q on file with the SEC for a description of these risks. All forward-looking statements are based on information currently available to Royalty Pharma and we assume no obligation to update any such forward-looking statements.
Non-GAAP financial measures will be used to help you understand our financial performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release available on our website.
With that, please advance to Slide 4. Our speakers on the call today are Pablo Legorreta, Founder and Chief Executive Officer; Marshall Urist, EVP, Head of Research and Investment, and Terry Coyne, EVP and Chief Financial Officer. Pablo will discuss a few highlights, Marshall will then provide a portfolio update, after which Terry will review the financials. Following concluding remarks from Pablo, we will hold a Q&A session when we will be joined by Chris Hite, EVP and Vice Chairman.
With that, I’d like to turn the call over to Pablo.
Pablo Legorreta
Thank you George, and welcome to everyone on the call. I am delighted to report another solid quarter of execution against our strategy as the leading funder of innovation in life sciences. Slide 6 summarizes our financial achievements in the second quarter, which again demonstrates our strong momentum and the power of our business model.